Observational studyJapanese journal of ophthalmology2025
Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.
Observational study in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oral methotrexate as a steroid-sparing therapy after high-dose intravenous corticosteroid pulse therapy for refractory Vogt-Koyanagi-Harada disease.Japanese journal of ophthalmology · 2026Article
- CD14+CD56+ Cell Is an Independent Regulatory Monocyte Subpopulation Increased in VKHS Patients Following Glucocorticoids Therapy.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHigh-dose steroid therapy is commonly used for Vogt-Koyanagi-Harada (VKH) disease in Japan, but the optimal initial dose remains uncertain. This study investigated the efficacy and safety of conventional steroid pulse therapy (pulse group) and half-dose steroid pulse therapy (half-pulse group) for the initial treatment of VKH disease. STUDY
designThis was a single-center, retrospective observational study based on a review of medical records. SUBJECTS AND
methodsSeventy-two patients with initial-onset VKH disease treated at Tokyo Medical University Hospital were analyzed. The pulse group (44 patients) received 1000 mg/day of intravenous methylprednisolone (MPSL), while the half-pulse group (28 patients) received 500 mg/day of MPSL. In both groups, steroids were tapered according to ocular findings, and the minimum follow-up period was eight months.
resultsRecurrence rate during follow-up period (pulse group: 41%, half-pulse group: 34%, p = 0.48), mean number of recurrences (pulse group: 1.9 ± 1.2, half-pulse group: 1.5 ± 0.9, p = 0.42), and type of recurrence (anterior uveitis: pulse group: 11%, half-pulse group: 17%, p = 0.33; posterior inflammation: pulse group: 34%, half-pulse group: 22%, p = 0.14) were not significantly different between the two groups. The proportion of patients requiring cataract surgery during the follow-up period tended to be higher in the pulse group (pulse group: 10%, half-pulse group: 3%, p = 0.12), although not significantly different. The incidence of sunset glow fundus was not significantly different between the two groups (pulse group: 23%, half-pulse group: 10%, p = 0.22).
conclusionsNo significant difference in clinical efficacy for VKH disease was observed between conventional steroid pulse therapy and half-pulse therapy, and by reducing the total steroid dose, half-pulse therapy potentially lowers the risk of adverse effects related corticosteroid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.